Sionna Therapeutics Inc. (SION)
| Bid | 6.87 |
| Market Cap | 350.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -5.48 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.35 |
| Volume | 122,526 |
| Avg. Volume (20D) | 264,102 |
| Open | 7.66 |
| Previous Close | 7.66 |
| Day's Range | 7.25 - 8.02 |
| 52-Week Range | 7.25 - 25.19 |
| Beta | 0.00 |
About SION
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator....
Analyst Forecast
According to 1 analyst ratings, the average rating for SION stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 302.77% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO WeekTwo sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...
2 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOsFive IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
2 months ago · seekingalpha.com
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis TreatmentsSionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in ca...